Skip to main content
Top
Published in: Endocrine 3/2020

01-06-2020 | Hypoparathyroidism | Original Article

The calcium-to-phosphorous (Ca/P) ratio in the diagnosis of primary hyperparathyroidism and hypoparathyroidism: a multicentric study

Authors: Bruno Madeo, Sara De Vincentis, Andrea Repaci, Paola Altieri, Valentina Vicennati, Elda Kara, Fabio Vescini, Pierluigi Amadori, Antonio Balestrieri, Uberto Pagotto, Manuela Simoni, Vincenzo Rochira

Published in: Endocrine | Issue 3/2020

Login to get access

Abstract

Purpose

The diagnosis of primary hyperparathyroidism (PHPT) and chronic hypoparathyroidism (HypoPT) is still challenging, especially in patients asymptomatic or with non-classical phenotypes and for physicians not skilled in calcium-phosphorous (Ca–P) disorders. The serum calcium/phosphorous (Ca/P) ratio has been proposed as accurate index to identify PHPT, while it has never been tested in HypoPT. The aim of this study is to investigate the diagnostic power of the serum Ca/P ratio in the diagnosis of primary parathyroid dysfunctions (both PHPT and HypoPT) in a large series of data.

Methods

A multicentric, retrospective, cross-sectional study (ClinicalTrials.gov: NCT03747029) was carried out including 432 PHPT patients and 217 HypoPT patients compared with 389 controls. Serum Ca, P, creatinine, parathyroid hormone and 25OH-vitamin D were collected. Serum Ca and P were expressed in mmol/L. Ca/P diagnostic performance was evaluated by receiver operating characteristic (ROC) curve, sensitivity, specificity and accuracy.

Results

The Ca/P ratio was significantly higher in PHPT and lower in HypoPT patients than controls (p < 0.0001). At ROC curve analysis, the Ca/P ratio above 2.55 was defined to identify PHPT patients (sensitivity 85.7%, specificity 85.3%) and below 1.78 to identify HypoPT patients (sensitivity 88.2%, specificity 87.9%).

Conclusions

The Ca/P ratio is a highly accurate index to identify PHPT when Ca/P is above 2.55 and HypoPT when it is below 1.78. These results demonstrate the reliability of this index to rule in/out primary parathyroid dysfunctions and remark the importance of measuring serum P in clinical practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference J.L. Shaker, L. Deftos. Calcium and Phosphate Homeostasis. [Updated 2018 Jan 19]. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 J.L. Shaker, L. Deftos. Calcium and Phosphate Homeostasis. [Updated 2018 Jan 19]. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000
2.
go back to reference M.D. Walker, S.J. Silverberg, Primary hyperparathyroidism. Nat. Rev. Endocrinol. 14, 115–125 (2018)CrossRef M.D. Walker, S.J. Silverberg, Primary hyperparathyroidism. Nat. Rev. Endocrinol. 14, 115–125 (2018)CrossRef
3.
go back to reference S. Minisola, L. Gianotti, S. Bhadada, S.J. Silverberg, Classical complications of primary hyperparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 32, 791–803 (2018)CrossRef S. Minisola, L. Gianotti, S. Bhadada, S.J. Silverberg, Classical complications of primary hyperparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 32, 791–803 (2018)CrossRef
4.
go back to reference M. Peacock, Calcium metabolism in health and disease. Clin. J. Am. Soc. Nephrol. 5(Suppl 1), S23–S30 (2010)CrossRef M. Peacock, Calcium metabolism in health and disease. Clin. J. Am. Soc. Nephrol. 5(Suppl 1), S23–S30 (2010)CrossRef
5.
go back to reference B. Madeo, S. De Vincentis, E. Kara, F. Vescini, T. Trenti, et al. Reliability of calcium-phosphorus (Ca/P) ratio as a new, accurate and inexpensive tool inthe diagnosis of some Ca-P disorders. J. Endocrinol. Investig. 42, 1041–1049 (2019) B. Madeo, S. De Vincentis, E. Kara, F. Vescini, T. Trenti, et al. Reliability of calcium-phosphorus (Ca/P) ratio as a new, accurate and inexpensive tool inthe diagnosis of some Ca-P disorders. J. Endocrinol. Investig. 42, 1041–1049 (2019)
6.
go back to reference M. Mannstadt, J.P. Bilezikian, R.V. Thakker, F.M. Hannan, B.L. Clarke et al. Hypoparathyroidism. Nat. Rev. Dis. Prim. 3, 17055 (2017)CrossRef M. Mannstadt, J.P. Bilezikian, R.V. Thakker, F.M. Hannan, B.L. Clarke et al. Hypoparathyroidism. Nat. Rev. Dis. Prim. 3, 17055 (2017)CrossRef
7.
go back to reference B. Madeo, E. Kara, K. Cioni, S. Vezzani, T. Trenti et al. Serum calcium to phosphorous (Ca/P) ratio is a simple, inexpensive, and accurate tool in the diagnosis of primary hyperparathyroidism. JBMR 2, 109–117 (2018) B. Madeo, E. Kara, K. Cioni, S. Vezzani, T. Trenti et al. Serum calcium to phosphorous (Ca/P) ratio is a simple, inexpensive, and accurate tool in the diagnosis of primary hyperparathyroidism. JBMR 2, 109–117 (2018)
8.
go back to reference J.P. Bilezikian, L. Bandeira, A. Khan, N.E. Cusano, Hyperparathyroidism. Lancet 391, 168–178 (2018)CrossRef J.P. Bilezikian, L. Bandeira, A. Khan, N.E. Cusano, Hyperparathyroidism. Lancet 391, 168–178 (2018)CrossRef
9.
go back to reference S.J. Silverberg, J.P. Bilezikian, “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J. Clin. Endocrinol. Metab. 88, 5348–5352 (2003)CrossRef S.J. Silverberg, J.P. Bilezikian, “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J. Clin. Endocrinol. Metab. 88, 5348–5352 (2003)CrossRef
10.
go back to reference A.N. Hollenberg, A. Arnold, Hypercalcemia with low-normal serum intact PTH: a novel presentation of primary hyperparathyroidism. Am. J. Med. 91, 547–548 (1991)CrossRef A.N. Hollenberg, A. Arnold, Hypercalcemia with low-normal serum intact PTH: a novel presentation of primary hyperparathyroidism. Am. J. Med. 91, 547–548 (1991)CrossRef
11.
go back to reference S. Corbetta, Normocalcemic hyperparathyroidism. Front. Horm. Res. 51, 23–39 (2019)CrossRef S. Corbetta, Normocalcemic hyperparathyroidism. Front. Horm. Res. 51, 23–39 (2019)CrossRef
13.
go back to reference C. Marcocci, F. Cetani, Clinical practice. Primary hyperparathyroidism. N. Engl. J. Med. 365, 2389–2397 (2011)CrossRef C. Marcocci, F. Cetani, Clinical practice. Primary hyperparathyroidism. N. Engl. J. Med. 365, 2389–2397 (2011)CrossRef
14.
go back to reference J.P. Bilezikian, M.L. Brandi, R. Eastell, S.J. Silverberg, R. Udelsman et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3561–3569 (2014)CrossRef J.P. Bilezikian, M.L. Brandi, R. Eastell, S.J. Silverberg, R. Udelsman et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3561–3569 (2014)CrossRef
15.
go back to reference M.M. Tuna, M. Caliskan, M. Unal, T. Demirci, B.A. Dogan et al. Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J. Bone Min. Metab. 34, 331–335 (2016)CrossRef M.M. Tuna, M. Caliskan, M. Unal, T. Demirci, B.A. Dogan et al. Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J. Bone Min. Metab. 34, 331–335 (2016)CrossRef
16.
go back to reference D. Shoback, Clinical practice. Hypoparathyroidism. N. Engl. J. Med. 359, 391–403 (2008)CrossRef D. Shoback, Clinical practice. Hypoparathyroidism. N. Engl. J. Med. 359, 391–403 (2008)CrossRef
17.
go back to reference M.L. Brandi, J.P. Bilezikian, D. Shoback, R. Bouillon, B.L. Clarke et al. Management of hypoparathyroidism: summary statement and guidelines. J. Clin. Endocrinol. Metab. 101, 2273–2283 (2016)CrossRef M.L. Brandi, J.P. Bilezikian, D. Shoback, R. Bouillon, B.L. Clarke et al. Management of hypoparathyroidism: summary statement and guidelines. J. Clin. Endocrinol. Metab. 101, 2273–2283 (2016)CrossRef
18.
go back to reference J. Bollerslev, L. Rejnmark, C. Marcocci, D.M. Shoback, A. Sitges-Serra et al. European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults. Eur. J. Endocrinol. 173, G1–G20 (2015)CrossRef J. Bollerslev, L. Rejnmark, C. Marcocci, D.M. Shoback, A. Sitges-Serra et al. European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults. Eur. J. Endocrinol. 173, G1–G20 (2015)CrossRef
19.
go back to reference D.M. Shoback, J.P. Bilezikian, A.G. Costa, D. Dempster, H. Dralle et al. Presentation of hypoparathyroidism: etiologies and clinical features. J. Clin. Endocrinol. Metab. 101, 2300–2312 (2016)CrossRef D.M. Shoback, J.P. Bilezikian, A.G. Costa, D. Dempster, H. Dralle et al. Presentation of hypoparathyroidism: etiologies and clinical features. J. Clin. Endocrinol. Metab. 101, 2300–2312 (2016)CrossRef
20.
go back to reference N.E. Cusano, J.P. Bilezikian, Signs and symptoms of hypoparathyroidism. Endocrinol. Metab. Clin. N. Am. 47, 759–770 (2018)CrossRef N.E. Cusano, J.P. Bilezikian, Signs and symptoms of hypoparathyroidism. Endocrinol. Metab. Clin. N. Am. 47, 759–770 (2018)CrossRef
21.
go back to reference L. Cianferotti, G. Marcucci, M.L. Brandi, Causes and pathophysiology of hypoparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 32, 909–925 (2018)CrossRef L. Cianferotti, G. Marcucci, M.L. Brandi, Causes and pathophysiology of hypoparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 32, 909–925 (2018)CrossRef
22.
go back to reference E.A. Alore, J.W. Suliburk, D.J. Ramsey, N.N. Massarweh, C.J. Balentine, et al. Diagnosis and Management of Primary Hyperparathyroidism Across theVeterans Affairs Health Care System. JAMA Intern Med. 179, 1220–1227 (2019) E.A. Alore, J.W. Suliburk, D.J. Ramsey, N.N. Massarweh, C.J. Balentine, et al. Diagnosis and Management of Primary Hyperparathyroidism Across theVeterans Affairs Health Care System. JAMA Intern Med. 179, 1220–1227 (2019)
23.
go back to reference J. Bollerslev, C. Schalin-Jantti, L. Rejnmark, H. Siggelkow, H. Morreau et al. Management of endocrine disease: unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur. J. Endocrinol. 181, P1–p19 (2019)CrossRef J. Bollerslev, C. Schalin-Jantti, L. Rejnmark, H. Siggelkow, H. Morreau et al. Management of endocrine disease: unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur. J. Endocrinol. 181, P1–p19 (2019)CrossRef
24.
go back to reference M. Pawlowska, N.E. Cusano, An overview of normocalcemic primary hyperparathyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 22, 413–421 (2015)CrossRef M. Pawlowska, N.E. Cusano, An overview of normocalcemic primary hyperparathyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 22, 413–421 (2015)CrossRef
25.
go back to reference N.E. Cusano, C. Cipriani, J.P. Bilezikian, Management of normocalcemic primary hyperparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 32, 837–845 (2018)CrossRef N.E. Cusano, C. Cipriani, J.P. Bilezikian, Management of normocalcemic primary hyperparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 32, 837–845 (2018)CrossRef
26.
go back to reference H. Lowe, D.J. McMahon, M.R. Rubin, J.P. Bilezikian, S.J. Silverberg, Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab. 92, 3001–3005 (2007)CrossRef H. Lowe, D.J. McMahon, M.R. Rubin, J.P. Bilezikian, S.J. Silverberg, Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab. 92, 3001–3005 (2007)CrossRef
27.
go back to reference L. Underbjerg, T. Sikjaer, L. Rejnmark, Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study. J. Bone Min. Res. 33, 822–831 (2018)CrossRef L. Underbjerg, T. Sikjaer, L. Rejnmark, Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study. J. Bone Min. Res. 33, 822–831 (2018)CrossRef
28.
go back to reference M.C. Astor, K. Lovas, A. Debowska, E.F. Eriksen, J.A. Evang et al. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J. Clin. Endocrinol. Metab. 101, 3045–3053 (2016)CrossRef M.C. Astor, K. Lovas, A. Debowska, E.F. Eriksen, J.A. Evang et al. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J. Clin. Endocrinol. Metab. 101, 3045–3053 (2016)CrossRef
29.
go back to reference M.R. Rubin, Skeletal manifestations of hypoparathyroidism. Bone 120, 548–555 (2019)CrossRef M.R. Rubin, Skeletal manifestations of hypoparathyroidism. Bone 120, 548–555 (2019)CrossRef
30.
go back to reference B.L. Clarke, Epidemiology and complications of hypoparathyroidism. Endocrinol. Metab. Clin. N. Am. 47, 771–782 (2018)CrossRef B.L. Clarke, Epidemiology and complications of hypoparathyroidism. Endocrinol. Metab. Clin. N. Am. 47, 771–782 (2018)CrossRef
31.
go back to reference I.H. de Boer, T.C. Rue, B. Kestenbaum, Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis. 53, 399–407 (2009)CrossRef I.H. de Boer, T.C. Rue, B. Kestenbaum, Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis. 53, 399–407 (2009)CrossRef
32.
go back to reference W.C. O’Neill, The fallacy of the calcium-phosphorus product. Kidney Int. 72, 792–796 (2007)CrossRef W.C. O’Neill, The fallacy of the calcium-phosphorus product. Kidney Int. 72, 792–796 (2007)CrossRef
Metadata
Title
The calcium-to-phosphorous (Ca/P) ratio in the diagnosis of primary hyperparathyroidism and hypoparathyroidism: a multicentric study
Authors
Bruno Madeo
Sara De Vincentis
Andrea Repaci
Paola Altieri
Valentina Vicennati
Elda Kara
Fabio Vescini
Pierluigi Amadori
Antonio Balestrieri
Uberto Pagotto
Manuela Simoni
Vincenzo Rochira
Publication date
01-06-2020
Publisher
Springer US
Published in
Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02276-7

Other articles of this Issue 3/2020

Endocrine 3/2020 Go to the issue